LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

NVS

145.46

+0.64%↑

MRK

113.2

+0.05%↑

Home・Akciju saraksts・Avidity Biosciences Inc

Avidity Biosciences Inc

Slēgts

SektorsVeselības aprūpe

15.05

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

15.05

Max

15.05

Galvenie mērījumi
By Trading Economics
Ienākumi	-63M -237M
Pārdošana	-12M 860K
EPS	-1.27
Peļņas marža	-27,569.884
Darbinieki	511
EBITDA	-59M -232M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	-0.1% downside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-9B 2.3B
Iepriekšējā atvēršanas cena	15.05
Iepriekšējā slēgšanas cena	15.05

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

25.575 / 32.65 Atbalsts un pretestība

Avidity Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. marts 23:01 UTC

Peļņas

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

2026. g. 5. marts 21:54 UTC

Peļņas

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

2026. g. 5. marts 21:35 UTC

Galvenie tirgus virzītāji

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

2026. g. 6. marts 00:00 UTC

Galvenie ziņu notikumi

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

2026. g. 5. marts 23:46 UTC

Tirgus saruna

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

2026. g. 5. marts 23:33 UTC

Tirgus saruna

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026. g. 5. marts 23:27 UTC

Tirgus saruna

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

2026. g. 5. marts 22:54 UTC

Tirgus saruna

Peļņas

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

2026. g. 5. marts 22:50 UTC

Tirgus saruna

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

2026. g. 5. marts 22:48 UTC

Peļņas

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026. g. 5. marts 22:46 UTC

Peļņas

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

2026. g. 5. marts 22:44 UTC

Peļņas

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 5. marts 21:35 UTC

Peļņas

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026. g. 5. marts 21:32 UTC

Peļņas

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026. g. 5. marts 21:26 UTC

Peļņas

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

2026. g. 5. marts 21:24 UTC

Peļņas

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

2026. g. 5. marts 21:23 UTC

Peļņas

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

2026. g. 5. marts 21:22 UTC

Peļņas

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026. g. 5. marts 21:21 UTC

Peļņas

Costco February Digitally-Enabled Sales Rose 21.8% >COST

2026. g. 5. marts 21:21 UTC

Peļņas

Costco Total Co Comparable Sales for February Rose 7.9% >COST

2026. g. 5. marts 21:20 UTC

Peļņas

Costco February Net Sales Were $21.69 B >COST

2026. g. 5. marts 21:20 UTC

Peļņas

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026. g. 5. marts 21:20 UTC

Peļņas

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026. g. 5. marts 21:19 UTC

Peļņas

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

2026. g. 5. marts 21:18 UTC

Peļņas

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

2026. g. 5. marts 21:18 UTC

Peļņas

Costco 2Q Same-Store Sales Up 7.4% >COST

2026. g. 5. marts 21:15 UTC

Peļņas

Costco 2Q EPS $4.58 >COST

Salīdzinājums

Cenas izmaiņa

Avidity Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

-0.1% uz leju

Prognoze 12 mēnešiem

Vidējais 72.75 USD -0.1%

Augstākais 75 USD

Zemākais 72 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Avidity Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Avidity Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

25.575 / 32.65Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Recent bearish events outweigh bullish events.

Finanšu rādītāji

Par Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.